Cargando…

Biomarker Discordances and Alterations Observed in Breast Cancer Treated with Neoadjuvant Chemotherapy: Causes, Frequencies, and Clinical Significances

Purpose: Biomarker discordances and alterations can be encountered between tru-cut biopsy and residual tumor in breast cancer treated with neoadjuvant chemotherapy (NACTx). We aimed to investigate the effect of NACTx on major biomarker expression (ER, PR, HER2, Ki-67) and tumor grade, the frequency...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yilmaz, Cengiz, Cavdar, Demet Kocatepe
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776827/ https://www.ncbi.nlm.nih.gov/pubmed/36547175 http://dx.doi.org/10.3390/curroncol29120761

Ejemplares similares

Predictors of lymphovascular invasion in estrogen receptor positive/Her-2 negative breast cancer patients treated with neoadjuvant chemotherapy
por: ÇAVDAR, Eyyüp, et al.
Publicado: (2022)

Prognostic and Predictive Significance of MYC and KRAS Alterations in Breast Cancer from Women Treated with Neoadjuvant Chemotherapy
por: Pereira, Cynthia Brito Lins, et al.
Publicado: (2013)

A logarithmic model for hormone receptor-positive and breast cancer patients treated with neoadjuvant chemotherapy
por: Şeber, Erdoğan Selçuk, et al.
Publicado: (2023)

Prognostic Significance of Inner Quadrant Involvement in Breast Cancer Treated with Neoadjuvant Chemotherapy
por: Chang, Ji Hyun, et al.
Publicado: (2016)

Significance of circulating tumor cells in osteosarcoma patients treated by neoadjuvant chemotherapy and surgery
por: Wu, Zhen-Jie, et al.
Publicado: (2018)

The Oncologic Safety of Sentinel Lymph Node Biopsy in Patients with Node-Positive Breast Cancer with Complete Response to Neoadjuvant Chemotherapy: A Single-Center Experience
por: Tercan, Ismail Can, et al.
Publicado: (2023)

Predictive significance of DNA damage and repair biomarkers in triple-negative breast cancer patients treated with neoadjuvant chemotherapy: An exploratory analysis
por: Vici, Patrizia, et al.
Publicado: (2015)

Proteomic alterations associated with residual disease in neoadjuvant chemotherapy treated ovarian cancer tissues
por: Penick, Emily R., et al.
Publicado: (2022)

Example of a Simulation Design in Nursing Education: Safe Chemotherapy Administration
por: Uslu, Yasemin, et al.
Publicado: (2019)

Prognostic Potential of Immune Inflammatory Biomarkers in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy
por: Truffi, Marta, et al.
Publicado: (2022)

Biomarker Alteration after Neoadjuvant Endocrine Therapy or Chemotherapy in Estrogen Receptor-Positive Breast Cancer
por: Long, Mengping, et al.
Publicado: (2022)

The Immunoscore in Localized Urothelial Carcinoma Treated with Neoadjuvant Chemotherapy: Clinical Significance for Pathologic Responses and Overall Survival
por: Nassif, Elise F., et al.
Publicado: (2021)

DNA Damage and Repair Biomarkers in Cervical Cancer Patients Treated with Neoadjuvant Chemotherapy: An Exploratory Analysis
por: Vici, Patrizia, et al.
Publicado: (2016)

Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
por: Radosevic-Robin, Nina, et al.
Publicado: (2021)

Impact on survival of estrogen receptor, progesterone receptor and Ki-67 expression discordance pre- and post-neoadjuvant chemotherapy in breast cancer
por: Ding, Yuqin, et al.
Publicado: (2020)

Alterations of biomarker profiles after neoadjuvant chemotherapy in breast cancer: tumor heterogeneity should be taken into consideration
por: Zhou, Xingchen, et al.
Publicado: (2015)

Biomarker evaluation in radically resectable locally advanced gastric cancer treated with neoadjuvant chemotherapy: an evidence reappraisal
por: Gervaso, Lorenzo, et al.
Publicado: (2021)

Dynamic alteration and prognostic significance of tumor‐associated CD68(+) and CD68(+)PD‐L1(−) macrophages in muscle‐invasive bladder cancer treated with neoadjuvant chemotherapy
por: Wu, Jie, et al.
Publicado: (2022)

Prognostic significance of p53 immunoexpression in the survival of oral squamous cell carcinoma patients treated with surgery and neoadjuvant chemotherapy
por: LI, LI, et al.
Publicado: (2013)

Prognostic significance of platelet-to-lymphocyte ratio (PLR) in patients with breast cancer treated with neoadjuvant chemotherapy: a meta-analysis
por: Qi, Xue, et al.
Publicado: (2023)

Couples and COVID-19 vaccination: Frequency and reasons for discordance
por: Schmaling, Karen B.
Publicado: (2022)

Biomarker dynamics and prognosis in breast cancer after neoadjuvant chemotherapy
por: Zarotti, Cristina, et al.
Publicado: (2022)

Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: An Observational Study
por: Shao, Zhiying, et al.
Publicado: (2016)

Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider
por: Geer, Eliza B., et al.
Publicado: (2019)

Significant Tumor Regression after Neoadjuvant Chemotherapy in Gastric Cancer, but Poor Survival of the Patient? Role of MHC Class I Alterations
por: Hiltner, Theresa, et al.
Publicado: (2023)

Perioperative discordance in mesothelioma cell type after pleurectomy/decortication—a possible detrimental effect of neoadjuvant chemotherapy due to epithelial to mesenchymal transition?
por: Ventura, Luigi, et al.
Publicado: (2023)

Assessment of response of neoadjuvant chemotherapy in carcinoma breast patients by high-frequency ultrasound
por: Dighe, Sajika, et al.
Publicado: (2022)

Discordant Responses Between Primary Head and Neck Tumors and Nodal Metastases Treated With Neoadjuvant Nivolumab: Correlation of Radiographic and Pathologic Treatment Effect
por: Merlino, Dante J., et al.
Publicado: (2020)

Discordant Alzheimer's neurodegenerative biomarkers and their clinical outcomes
por: Guo, Yu, et al.
Publicado: (2020)

Tissue Biomarkers in Prognostication of Serous Ovarian Cancer following Neoadjuvant Chemotherapy
por: Khandakar, Binny, et al.
Publicado: (2014)

The role of IRAK1 in breast cancer patients treated with neoadjuvant chemotherapy
por: Yang, Muwen, et al.
Publicado: (2019)

Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy
por: Choi, Chel Hun, et al.
Publicado: (2008)

Serum nucleosomes during neoadjuvant chemotherapy in patients with cervical cancer. Predictive and prognostic significance
por: Trejo-Becerril, Catalina, et al.
Publicado: (2005)

Prognostic significance of pathological complete response following neoadjuvant chemotherapy for operable breast cancer
por: KAWAJIRI, HIDEMI, et al.
Publicado: (2014)

Significance of intrinsic breast cancer subtypes on the long-term prognosis after neoadjuvant chemotherapy
por: Goto, Wataru, et al.
Publicado: (2018)

Neoadjuvant immunotherapy combined with chemotherapy significantly improved patients’ overall survival when compared with neoadjuvant chemotherapy in non-small cell lung cancer: A cohort study
por: Dai, Fuqiang, et al.
Publicado: (2022)

Serum biomarker profiles and response to neoadjuvant chemotherapy for locally advanced breast cancer
por: Nolen, Brian M, et al.
Publicado: (2008)

On-treatment biomarkers can improve prediction of response to neoadjuvant chemotherapy in breast cancer
por: Bownes, Richard J., et al.
Publicado: (2019)

FZR1 as a novel biomarker for breast cancer neoadjuvant chemotherapy prediction
por: Liu, Shuo, et al.
Publicado: (2020)

Identification of Novel Biomarkers in Pancreatic Tumor Tissue to Predict Response to Neoadjuvant Chemotherapy
por: Sahni, Sumit, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_rrbkfifme56gl8rsn7aomu0j1s